• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Advanced Therapeutics in Movement and Related Disorders Congress

The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease

June 18, 2022

In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.

Amantadine Delayed-Release/Extended-Release Capsules Show More Benefit Compared With Other Formulations

June 18, 2022

In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.

Social Prescribing and Advances in Therapy for Movement Disorders: Jean Hubble, MD

June 17, 2022

The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]

Opicapone Shows Comparable Efficacy, Safety Among Older Individuals With Parkinson Disease

June 17, 2022

The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.

Episode 62: Advanced Therapeutics in Parkinson and Movement Disorders

April 22, 2022

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Yasar Torres-Yaghi, MD.